Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study-Reference-Cited by-同舟云学术

Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study

Published:2018-03-12 Issue:7 Volume:65 Page:e27034
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Dvorak Christopher C.¹^ORCID,Satwani Prakash²,Stieglitz Elliot³^ORCID,Cairo Mitchell S.⁴^ORCID,Dang Ha⁵⁶,Pei Qinglin⁶,Gao Yun⁶,Wall Donna⁷,Mazor Tali³,Olshen Adam B.⁸,Parker Joel S.⁹,Kahwash Samir¹⁰,Hirsch Betsy¹¹,Raimondi Susana¹²,Patel Neil¹³,Skeens Micah¹⁴,Cooper Todd¹⁵,Mehta Parinda A.¹⁶,Grupp Stephan A.¹⁷,Loh Mignon L.³

Affiliation:

1. Division of Pediatric Allergy, Immunology & Bone Marrow Transplantation; Benioff Children's Hospital; University of California San Francisco; San Francisco California

2. Division of Pediatric Hematology, Oncology & Stem Cell Transplant; Columbia University; New York New York

3. Division of Pediatric Hematology/Oncology, Benioff Children's Hospital; University of California San Francisco; San Francisco California

4. Division of Pediatric Hematology, Oncology and Stem Cell Transplantation; Maria Fareri Children's Hospital; Westchester Medical Center; New York Medical College; Valhalla New York New York

5. Division of Preventative Medicine; University of Southern California; Children's Oncology Group; Monrovia California

6. Children's Oncology Group; Monrovia California

7. Division of Haematology/Oncology; Hospital for Sick Children; Toronto Canada

8. Department of Epidemiology and Biostatistics; University of California San Francisco; San Francisco California

9. Division of Cancer Genetics; University of North Carolina; Chapel Hill North Carolina

10. Department of Laboratory Medicine/Anatomic Pathology; Nationwide Children's Hospital; Columbus Ohio

11. Department of Laboratory Medicine and Pathology; University of Minnesota; Minneapolis Minnesota

12. Department of Pathology; St. Jude Children's Research Hospital; Memphis Tennessee

13. Department of Pharmacy Services; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

14. Division of Hematology/Oncology/Bone Marrow Transplantation; Nationwide Children's Hospital; Columbus Ohio

15. Division of Pediatric Hematology/Oncology; Seattle Children's Hospital; Seattle WA

16. Division of Bone Marrow Transplantation and Immune Deficiency; Cincinnati Children's Hospital Medical Center; Cincinnati Ohio

17. Division of Oncology; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

Funder

National Institutes of Health

Leukemia and Lymphoma Society

National Cancer Institute

St. Baldrick's Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference41 articles.

1. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial;Locatelli;Blood,2005

2. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study;Locatelli;Blood,2013

3. Juvenile myelomonocytic leukemia;Arico;Blood,1997

4. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria;Bergstraesser;Pediatr Blood Cancer,2007

5. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia;Chang;Blood,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study;Frontiers in Immunology;2024-08-26

2. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group;Cancer Discovery;2024-06-11

3. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11;Transplantation and Cellular Therapy;2024-01

4. Allogeneic Hematopoietic Cell Transplantation in Pediatric MDS Including Refractory Cytopenia of Childhood and in Juvenile Myelomonocytic Leukemia;The EBMT Handbook;2024

5. Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases;npj Systems Biology and Applications;2023-09-09